KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Ten-year safety and clinical benefit from open-label etanercept treatment in children and young adults with juvenile idiopathic arthritis. PMID 37140539 · Rheumatology (Oxford) · 2024-Jan-04 The report is a long-term safety and efficacy extension study of etanercept in juvenile idiopathic arthritis (a rheumatologic condition, not oncology). It is a Phase III open-label study (not randomized). The primary endpoint is the occurrence of malignancy (a safety event), not a time-to-event efficacy endpoint (e.g., OS, PFS) for a cancer trial. Efficacy endpoints are categorical response criteria (ACR, JADAS), not time-to-event outcomes. Therefore, it does not meet the eligibility criteria for an oncology Phase III randomized trial with a drug-containing intervention and a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial. PMID 38172131 · Nat Commun · 2024-Jan-03 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Organ Preservation and Survival by Clinical Response Grade in Patients With Rectal Cancer Treated With Total Neoadjuvant Therapy: A Secondary Analysis of the OPRA Randomized Clinical Trial. PMID 38194231 · JAMA Netw Open · 2024-Jan-02 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Neoadjuvant camrelizumab and apatinib combined with chemotherapy versus chemotherapy alone for locally advanced gastric cancer: a multicenter randomized phase 2 trial. PMID 38167806 · Nat Commun · 2024-Jan-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial. PMID 38167503 · Nat Commun · 2024-Jan-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
ERASURE: early autologous blood pleurodesis for postoperative air leaks-a randomized, controlled trial comparing prophylactic autologous blood pleurodesis versus standard watch and wait treatment for postoperative air leaks following thoracoscopic anatomic lung resections. PMID 38166982 · Trials · 2024-Jan-02 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer. PMID 38166784 · BMC Cancer · 2024-Jan-02 The study is a retrospective analysis of a retrospective cohort, not a prospective randomized controlled trial of a specific phase (II or III). While the publication type is 'Randomized Controlled Trial', the methods describe a retrospective analysis of 214 patients, with a subsequent random split into training/validation sets for nomogram development, not randomization to treatment arms. This is a secondary analysis for predictive modeling, not a primary efficacy report of a Phase III or II/III randomized trial. The phase is not explicitly established as Phase III or II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Autotaxin Secretion Is a Stromal Mechanism of Adaptive Resistance to TGFβ Inhibition in Pancreatic Ductal Adenocarcinoma. PMID 37738399 · Cancer Res · 2024-Jan-02 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
A comparative study of whole brain radiotherapy with concomitant thalidomide versus whole brain radiotherapy alone in brain metastases. PMID 38554330 · J Cancer Res Ther · 2024-Jan-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Short Oral Antibiotic Therapy for Pediatric Febrile Urinary Tract Infections: A Randomized Trial. PMID 38146260 · Pediatrics · 2024-Jan-01 The study is a randomized controlled trial in pediatrics for febrile urinary tract infection, not an oncology trial. It lacks any primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, EFS, RFS, TTP, or use of Kaplan-Meier/HR for efficacy. Therefore, it does not meet the eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Follow-Up of the Response-Adapted Intergroup EORTC/LYSA/FIL H10 Trial for Localized Hodgkin Lymphoma. PMID 37967311 · J Clin Oncol · 2024-Jan-01 The record describes a randomized trial in oncology with a drug intervention and a time-to-event endpoint (PFS). It is a primary report of final results. However, the trial phase is not explicitly stated in the provided metadata (title, abstract, or publication types). The deterministic review correctly identified that phase 3 evidence is unclear. Without explicit confirmation of Phase III/IIIb or Phase II/III status, eligibility cannot be established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Laser Epilation as an Adjunct to Standard Care in Reducing Pilonidal Disease Recurrence in Adolescents and Young Adults: A Randomized Clinical Trial. PMID 37938854 · JAMA Surg · 2024-Jan-01 The record is a randomized clinical trial in pilonidal disease, which is not an oncology/malignant neoplasm. It also lacks a drug intervention and a primary time-to-event efficacy endpoint (OS, PFS, etc.), which are required for inclusion in this cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Long-Term Follow-Up of the Response-Adjusted Therapy for Advanced Hodgkin Lymphoma Trial. PMID 37883739 · J Clin Oncol · 2024-Jan-01 The record describes a randomized trial with drug interventions and time-to-event endpoints (PFS, OS) in oncology. However, the provided metadata (title, abstract, publication types) does not explicitly state the trial phase (Phase III, II/III, etc.). Without explicit phase information, eligibility cannot be definitively established.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A Randomized Controlled Study on Clinical Adherence to Evidence-Based Guidelines in the Management of Simulated Patients With Barrett's Esophagus and the Clinical Utility of a Tissue Systems Pathology Test: Results From Q-TAB. PMID 37767993 · Clin Transl Gastroenterol · 2024-Jan-01 The study is a randomized controlled trial on a diagnostic test's impact on clinical guideline adherence for Barrett's esophagus, which is a precursor to esophageal cancer. However, it is not a Phase III definitive drug trial, does not involve a drug intervention (the intervention is a tissue systems pathology test), and does not report time-to-event efficacy endpoints like OS or PFS. Therefore, it does not meet the eligibility criteria for the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of two different methods for lymphadenectomy along the left recurrent laryngeal nerve by minimally invasive esophagectomy in patients with esophageal squamous cell carcinoma: a prospective randomized trial. PMID 37737902 · Int J Surg · 2024-Jan-01 The study is an oncology RCT with time-to-event endpoints, but it does not involve a drug-containing intervention (it compares surgical techniques). Therefore, it is excluded based on the drug intervention criterion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Conventional vs Short Duration of Antibiotics in Patients With Moderate or Severe Cholangitis: Noninferiority Randomized Trial. PMID 37732816 · Am J Gastroenterol · 2024-Jan-01 The study is a randomized trial of antibiotic duration for cholangitis, which is not an oncology malignancy study. It lacks a primary/key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS) as required.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Compliance and Toxicity of Total Neoadjuvant Therapy for Rectal Cancer: A Secondary Analysis of the OPRA Trial. PMID 37544412 · Int J Radiat Oncol Biol Phys · 2024-Jan-01 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Safety and feasibility clinical trial of nucleus accumbens deep brain stimulation for treatment-refractory opioid use disorder. PMID 37329519 · J Neurosurg · 2024-Jan-01 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Salivary Electrostimulation in the Treatment of Radiation Therapy-Induced Xerostomia (LEONIDAS-2): A Multicenter, Randomized, Double-Masked, Sham-Controlled, Phase 3 Trial. PMID 36933846 · Int J Radiat Oncol Biol Phys · 2024-Jan-01 干预为非药物单独策略,未满足药物干预要求。
H L B
旧查询独有 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
NeoSCORE II: three vs four cycles of neoadjuvant sintilimab + chemotherapy for squamous non-small-cell lung cancer. PMID 38353107 · Future Oncol · 2024-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Association between the antiadhesion membrane and small bowel obstruction after open gastrectomy: A supplemental analysis of the randomized controlled JCOG1001 trial. PMID 38250686 · Ann Gastroenterol Surg · 2024-Jan The study is a randomized surgical trial in oncology patients, but it does not involve a drug-containing intervention as defined by the criteria. The intervention is a physical antiadhesion membrane used during surgery, not a systemic drug therapy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of the effects of open and laparoscopic approach on body composition in gastrectomy for gastric cancer: A propensity score-matched study. PMID 38250677 · Ann Gastroenterol Surg · 2024-Jan 干预为非药物单独策略,未满足药物干预要求。
H B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Efficacy, Safety, Pharmacokinetics, and Immunogenicity of DRL-Trastuzumab Versus Herceptin in Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Randomized Controlled Trial. PMID 38237093 · JCO Glob Oncol · 2024-Jan The record describes a randomized trial of a biosimilar in HER2-positive metastatic breast cancer with a primary endpoint of overall response rate (ORR), not a time-to-event efficacy endpoint like OS, PFS, or DFS. While PFS6 rate was a secondary endpoint, the primary endpoint is not a key time-to-event measure, and the trial phase (Phase III/IIIb or II/III) is not explicitly stated in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Preventing lower limb lymphedema after pelvic lymphadenectomy with progressive resistance exercise training: A randomized controlled trial. PMID 38188370 · Asia Pac J Oncol Nurs · 2024-Jan The study is a randomized controlled trial in oncology (cervical cancer) with a time-to-event endpoint (HR for lymphedema incidence), but it does not meet the core eligibility criteria: the intervention is non-drug (exercise training), and the endpoint is a toxicity/prevention outcome, not a standard oncology efficacy endpoint like OS or PFS. Phase evidence is also unclear.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Metformin in Conjunction With Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer: Long-term Results of a Prospective Phase II Clinical Trial. PMID 38159979 · Anticancer Res · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Correlation of multiple endpoints in the first-line chemotherapy of advanced gastric cancer: Pooled analysis of individual patient data from Japanese Phase III trials. PMID 38140879 · Cancer Med · 2024-Jan The record describes a pooled analysis of individual patient data from four Japanese Phase III trials in advanced gastric cancer. While it involves oncology, humans, Phase III trials, time-to-event endpoints, and drug interventions, it is not an original result report of a single randomized trial. Instead, it is a secondary analysis investigating correlations between endpoints. Therefore, it does not meet the inclusion criteria for a primary result report of an individual randomized trial.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Oral decitabine-cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. PMID 38135371 · Lancet Haematol · 2024-Jan The study is a randomized, phase 3 oncology trial comparing oral decitabine-cedazuridine to intravenous decitabine in myelodysplastic syndromes and chronic myelomonocytic leukaemia. However, the primary and reported efficacy endpoint is pharmacokinetic equivalence (area under the curve), not a time-to-event clinical outcome such as overall survival, progression-free survival, or any other endpoint typically analyzed with Kaplan-Meier or hazard ratios. The abstract focuses on safety and pharmacokinetics, with no mention of time-to-event analyses. Therefore, it does not meet the criterion for having a primary or key secondary time-to-event efficacy endpoint required for inclusion in this cohort.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of tirbanibulin 1% ointment in actinic keratoses: Data from two phase-III trials and the real-life clinical practice presented at the European Academy of Dermatology and Venereology Congress 2022. PMID 38116638 · J Eur Acad Dermatol Venereol · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Food Effect on the Pharmacokinetics of VC004, a Tropomyosin Receptor Kinase Inhibitor: A Randomized Crossover Trial in Healthy Chinese Subjects. PMID 38112942 · Clin Drug Investig · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer (KCSG-BR15-17): A randomized, open-label, multicenter, phase II trial. PMID 38104354 · Eur J Cancer · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study. PMID 38092009 · Lancet Oncol · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Similar effectiveness with primary HPV and cytology screening - Long-term follow-up of randomized cervical cancer screening trial. PMID 38091774 · Gynecol Oncol · 2024-Jan Study is an oncology randomized trial on cervical cancer screening (HPV vs cytology) with original results, but it lacks a drug-containing intervention and does not report a time-to-event efficacy endpoint (e.g., OS, PFS, DFS) using Kaplan-Meier or hazard ratios; it uses rate ratios for incidence and mortality.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Endoscopic En Bloc Versus Piecemeal Resection of Large Nonpedunculated Colonic Adenomas : A Randomized Comparative Trial. PMID 38079634 · Ann Intern Med · 2024-Jan The trial compares two endoscopic procedures (ESD vs. EMR) for large colonic adenomas. While randomized and reporting efficacy results, it lacks a drug-containing intervention and the primary endpoint (6-month local recurrence) is a binary outcome, not a time-to-event endpoint like OS, PFS, or DFS with Kaplan-Meier analysis.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Correction: Efficacy of GV1001 with gemcitabine/capecitabine in previously untreated patients with advanced pancreatic ductal adenocarcinoma having high serum eotaxin levels (KG4/2015): an open-label, randomised, Phase 3 trial. PMID 38049557 · Br J Cancer · 2024-Jan The record is for a published erratum correcting a prior trial report, not the original result report itself. The abstract is empty, and no time-to-event efficacy signal is present in the provided metadata. Therefore, the original result report cannot be confirmed from this record.
H B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. PMID 38043558 · Lancet Oncol · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Risk of Cutaneous T Cell Lymphoma with Psoriasis Biologic Therapies. PMID 38043065 · Dermatol Ther (Heidelb) · 2024-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
A randomised phase 2 study of intermittent versus continuous dosing of dabrafenib plus trametinib in patients with BRAFV600 mutant advanced melanoma (INTERIM). PMID 38029480 · Eur J Cancer · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Stentless florence robotic intracorporeal neobladder (FloRIN), a feasibility prospective randomized clinical trial. PMID 38011784 · Eur J Surg Oncol · 2024-Jan 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland. PMID 37999854 · Pharmacoecon Open · 2024-Jan 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Perioperative NALIRIFOX in patients with resectable pancreatic ductal adenocarcinoma: The open-label, multicenter, phase II nITRO trial. PMID 37995598 · Eur J Cancer · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Hematological Toxicity of PARP Inhibitors in Metastatic Prostate Cancer Patients with Mutations of BRCA or HRR Genes: A Systematic Review and Safety Meta-analysis. PMID 37993604 · Target Oncol · 2024-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Efficacy and safety of ripretinib vs. sunitinib in patients with advanced gastrointestinal stromal tumor previously treated with imatinib: A phase 2, multicenter, randomized, open-label study in China. PMID 37980854 · Eur J Cancer · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Association between gut microbiota and seven gastrointestinal diseases: A Mendelian randomized study. PMID 37957025 · J Gene Med · 2024-Jan The study is a Mendelian randomization investigation into associations between gut microbiota and gastrointestinal diseases. It is not a randomized clinical trial, has no drug intervention, and does not report a time-to-event efficacy endpoint like OS or PFS. Therefore, it fails multiple eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study. PMID 37945326 · J Gynecol Oncol · 2024-Jan The record is a clinical trial protocol/registration for a randomized study in oncology (ovarian cancer) with a drug-containing intervention and a time-to-event primary endpoint (PFS). However, it does not present final or interim results; it is a study-in-progress protocol, which is explicitly excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer. PMID 37935284 · Radiother Oncol · 2024-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Treosulfan vs busulfan conditioning for allogeneic bmt in children with nonmalignant disease: a randomized phase 2 trial. PMID 37925531 · Bone Marrow Transplant · 2024-Jan 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Efficacy and safety of SBRT for spine metastases: A systematic review and meta-analysis for preparation of an ESTRO practice guideline. PMID 37922993 · Radiother Oncol · 2024-Jan 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Impact of Imaging-Guided Localization on Performance of Tailored Axillary Surgery in Patients with Clinically Node-Positive Breast Cancer: Prospective Cohort Study Within TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101). PMID 37903951 · Ann Surg Oncol · 2024-Jan The record describes a prospective observational cohort study preplanned within a randomized Phase III trial (TAXIS/OPBC-03). While it is oncologic, human, and part of a randomized Phase III, it does not meet the core eligibility criteria: it is not a report of a drug-containing intervention (the focus is surgical technique/IGL), and it does not include a primary or key secondary time-to-event efficacy endpoint. The study reports on surgical performance metrics, not survival or progression outcomes.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction: a randomized, double-blinded, three-arm parallel-group, controlled trial. PMID 37897527 · Eur J Clin Pharmacol · 2024-Jan Study is a randomized, double-blind, three-arm trial evaluating empagliflozin and colchicine in patients with reduced left ventricular ejection fraction after ST-elevation myocardial infarction. Primary outcomes are changes in NYHA functional class and hs-CRP over 12 weeks, which are not time-to-event endpoints. While it includes drug interventions and is original, it fails the core requirement of a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR). Additionally, it is not an oncology study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Erdafitinib in BCG-treated high-risk non-muscle-invasive bladder cancer. PMID 37871701 · Ann Oncol · 2024-Jan The study is an oncology randomized trial with a drug intervention and primary RFS endpoint, but the trial phase (III/IIIb or II/III) is not explicitly stated in the provided abstract or metadata. The deterministic review signal indicates phase evidence is unclear.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -